US20030082664A1 - System for the detection of urease and method for using same - Google Patents
System for the detection of urease and method for using same Download PDFInfo
- Publication number
- US20030082664A1 US20030082664A1 US09/977,556 US97755601A US2003082664A1 US 20030082664 A1 US20030082664 A1 US 20030082664A1 US 97755601 A US97755601 A US 97755601A US 2003082664 A1 US2003082664 A1 US 2003082664A1
- Authority
- US
- United States
- Prior art keywords
- composition
- indicator
- urea
- urease
- well
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/58—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving urea or urease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/10—Enterobacteria
Definitions
- bacteria include those of the genus Campylobacter, and particularly Helicobacter pylori .
- Helicobacter pylori can cause bacterial infections on the mucosal surface of the gastrointestinal tract, particularly on the surface of the stomach.
- the chronic disorders of the gastrointestinal system that can be caused by bacteria include peptic ulcers, gastritis, and the like.
- Urease is known to convert urea into ammonium carbonate, which then decomposes into ammonia and carbon dioxide. Consequently, in the past, one test for detecting the presence of Helicobacter pylori included the steps of contacting a sample of gastric material with a composition containing urea and an indicator, namely a pH indicator that changes color when there is a rise in pH. If urease is present within the gastric material it breaks down the urea, which results in the formation of ammonia after further decomposition and causes the pH indicator to change color.
- the gastric material that is collected from the patient is typically a biopsy specimen that is removed from the gastric mucosa at endoscopy by means of biopsy forceps.
- the tissue sample is inserted into a gel that contains urea and the indicator.
- the testing composition used to detect the presence of urease has a limited shelf life.
- the urea and other reagents contained within the composition can have a tendency to degrade over time. Consequently, once formulated, the testing composition should be used in a relatively short amount of time and is also typically refrigerated prior to use in order to prevent degradation.
- the present invention is directed to further improvements in the detection of bacterial infections in the gastrointestinal tract.
- the present invention is directed to a system for detecting the presence of urease in a gastric sample in order to indicate the presence of Helicobacter pylori .
- the system includes a first composition that is maintained separate from a second composition for sequential contact with the sample.
- the first composition includes urea in a dried and finely powdered state.
- the urea is capable of being converted into ammonia when contacted with urease.
- the powdered urea can have a mean particle size of less than about 0.1 mm, and particularly less than about 0.05 mm.
- the first composition can also include other powder-like components, such as an anti-caking agent to prevent the fine urea from clumping or “caking”.
- the second composition can contain an indicator and can be configured to indicate the presence of ammonia.
- the indicator can be a pH indicator that changes color when the pH of the second composition is increased to a certain level.
- the indicator can be phenol red, which changes from yellow to red when exposed to a pH of greater than about 6.8.
- the gastric biopsy sample is first contacted with the first composition.
- the urea powder contacts and sticks to the gastric biopsy sample. Should the gastric sample contain urease, the urea is converted into ammonia.
- the gastric material is then contacted with the second composition containing the indicator.
- the indicator indicates the presence of ammonia that, in turn, is a positive test for the detection of urease.
- the urea remains more stable and therefore the system has an increased shelf life.
- the gel mixture is stable during manufacture so that much larger and longer duration production runs can be made without concern for slight temperature variations during the process.
- the second composition can contain various other ingredients.
- the second composition can be in a gel-like state and can contain a gel, such as agar.
- the second composition can also contain a pH adjuster, such as an acid or buffering agent.
- the pH adjuster can maintain the pH of the second composition in a range of from about 4.5 to about 6.
- the second composition can also contain a bactericide, which can inhibit the growth of other organisms.
- the first and second compositions can be contained within separate containers or can be spaced apart in the same container.
- a container can be used that includes a first well and a second well.
- the first composition can be located in the first well, while the second composition can be located in the second well.
- the container can be made from plastic and can include a peelable top made from a film.
- the film can be substantially or completely water impermeable over the first well to prevent any moisture from contacting the urea.
- the present invention is directed to a system for detecting the presence of urease in a gastric sample in which the gastric sample is contacted with a single composition.
- the composition includes urea and a dry indicator.
- the urea which is capable of being converted into ammonia when contacted with urease, is present in a dried and finely powdered state.
- the urea can have a mean particle size of less than about 0.1 mm.
- the dry indicator is configured to indicate the presence of ammonia.
- the indicator can be a pH indicator that changes color when the pH of the composition is increased above a certain level.
- the composition can further include an anti-caking agent and/or a bactericide.
- a gastric sample is contacted with the composition. Any liquids contained in the gastric sample can be used to activate the composition. Alternatively, a liquid, such as distilled water, can be added to the composition in conjunction with the gastric sample. If urease is present in the gastric sample, the urease breaks down urea into ammonia, which in turn activates the indicator.
- the present invention is further directed to a material well suited for detecting the presence of urease in a gastric material for diagnosing gastrointestinal disorders.
- the material includes a composition in the form of a powder.
- the composition can include urea and an anti-caking agent.
- the composition can further contain a dry indicator.
- FIG. 1 is a perspective view of one embodiment of a system for detecting urease in accordance with the present invention
- FIG. 2 is a top view of the system illustrated in FIG. 1;
- FIG. 3 is a cross-sectional view of the system illustrated in FIG. 1;
- FIG. 4 is a cross-sectional view of another embodiment of a urease testing device made in accordance with the present invention.
- the present invention is generally directed to a system and method for the detection of gastrointestinal disorders caused by bacterial infections. More particularly, the system and method of the present invention detect the presence of urease on a gastric biopsy sample.
- Urease is an enzyme known to be produced by bacteria that are harmful to the gastrointestinal tract, including bacteria such as Helicobacter pylori .
- Gastrointestinal disorders that can be caused by bacterial infections include chronic or atrophic gastritis, gastroenteritis, non-ulcer dyspepsia, esophageal reflux disease, gastric motility disorders, peptic ulcers including gastric and duodenal ulcers, and the like.
- a biopsy sample of gastric material was first obtained.
- the biopsy sample was then contacted with a composition containing urea and an indicator, such as a pH indicator. If urease were present in the biopsy sample, the urease would break down and convert the urea in the composition to ammonia subsequently causing a rise in the pH of the composition. The rise in pH then caused the indicator to undergo a color change.
- the composition containing urea and the indicator has a relatively short shelf life due to the instability of various ingredients in the composition, including the urea.
- the present invention is directed to an improved test for gastrointestinal disorders caused by bacterial infections.
- a composition containing urea is separated from a composition containing an indicator. The two compositions are then sequentially contacted with a biopsy sample in order to detect the presence of urease.
- the first composition contains urea in a finely powdered, dry state.
- urea in a powdered form separate from the agar and the indicator, the urea remains more stable.
- the handling requirements of the test system become more relaxed. For instance, by maintaining both compositions separate, there is no need to refrigerate the compositions prior to use or during shipping.
- the process conditions for manufacturing the indicator composition also become relaxed.
- the indicator composition such as an indicator gel, is much more stable during manufacture, allowing larger batches to be produced that are not sensitive to ingredients contained within the composition and to temperature variations.
- FIGS. 1 - 3 illustrate one exemplary embodiment of a device for detecting urease in biopsy samples in accordance with the present invention.
- the testing device in this embodiment includes a single container 10 defining a first well 12 and a second well 14 .
- Contained in the first well 12 is a first composition 16 containing urea, such as urea in a finely powdered state with or without an anti-caking agent.
- a second composition 18 containing an indicator is configured to detect the presence of ammonia.
- the device 10 further includes a removable top 20 that covers the first well 12 and the second well 14 .
- the top 20 can be made from a plastic film.
- the top 20 is provided in order to prevent the first composition 16 or the second composition 18 from spilling or becoming contaminated prior to use.
- the film top 20 can be made liquid impermeable at a location over the first well 12 .
- the entire film top 20 can be liquid impermeable or, alternatively, a separate membrane 22 as shown in FIG. 1 can be placed over the first well 12 that is liquid impermeable.
- the membrane 22 can also be used to prevent urea particles from sticking to the film top when the film top is removed.
- a biopsy sample is first taken from the lining of the gastrointestinal tract of a patient, such as from the lining of the stomach.
- the biopsy sample can be taken at endoscopy using biopsy forceps.
- the top film 20 is peeled back to expose the first composition 16 in the first well 12 .
- the biopsy sample is then contacted with the first composition causing the urea powder to stick to the sample.
- the biopsy sample can be rolled in the first composition much like the process of “flouring” a food product prior to cooking.
- the sample is then contacted with the second composition 18 containing an indicator located in the second well 14 .
- the powdered urea on the surface of the biopsy sample is moistened and activated by the second composition. Once moistened, the urea powder becomes available in greater amounts to any urease enzyme present in the biopsy sample. If present, the urease converts the urea into the unstable ammonium bicarbonate, which further decomposes into ammonia and carbon dioxide.
- the indicator present in the second composition indicates the presence of ammonia to signify a positive test for urease.
- the indicator can be a pH indicator that changes color when the pH of its environment is increased.
- first and second compositions of the present invention can be maintained in any suitable separated state prior to testing.
- first composition and the second composition can be maintained in separate containers if desired.
- the first composition is generally a dry or moisture-free composition containing urea in a powdered state.
- Urea has the chemical formula H 2 NCONH 2 and is a naturally occurring product of protein metabolism. When contacted with urease, urea hydrolyzes to form unstable ammonium bicarbonate, which further decomposes into ammonia and carbon dioxide.
- Urea in a powdered state for use in the present invention is available from various commercial sources.
- the particle size of the urea contained in the first composition is generally not critical although smaller particle sizes work more efficiently.
- the urea can be ground to have a mean particle size of less than about 0.1 mm, particularly less than 0.05 mm, and more particularly less than about 0.01 mm. It should be understood, however, that even smaller particle sizes may be used.
- the urea particles can have a mean particle size of less than 3 microns, and particularly less than 1 micron. By reducing the particle size, more surface area of urea is available for reaction with urease and the urea will better stick to the biopsy sample.
- the urea particles can have a particle size distribution such that no particles present have a size greater than about 100 microns, particularly no greater than about 10 microns, and more particularly no greater than about 5 microns.
- the particle size of the urea can be determined using any suitable method, such as by using transmission electron microscopy (TEM).
- TEM transmission electron microscopy
- the average diameter of each particle is measured, followed by calculating the mean diameter of the urea particles in a particular group.
- the average diameter of each particle can be calculated by taking the average of the smallest diameter of the particle and the largest diameter of the particle.
- light scattering can also be used to determine particle sizes.
- the mean particle size of the urea particles in a particular group is calculated by adding the sizes of the particles together and dividing by the number of particles.
- the first composition can also contain various other dry additives.
- an anti-caking agent can also be contained within the first composition.
- the anti-caking agent will prevent the fine urea powder from clumping or “caking”.
- Any suitable anti-caking agent can be used in the present invention.
- fine silicon dioxide or fine sodium alumino silicate powder can be contained in the first composition.
- the weight per weight (w/w) ratio of urea/silicon dioxide contained in the first composition can be any ratio from 1/1 to 100/1.
- the particle size of the anti-caking agent can vary depending upon the particular application. For instance, in one embodiment, the particle size of the anti-caking agent is no greater than the particle size of the urea.
- the second composition which is maintained separate from the first composition, contains an indicator for indicating the presence of ammonia.
- an indicator for indicating the presence of ammonia.
- any suitable indicator can be present in the second composition.
- a pH indicator can be used that indicates a change in pH.
- various pH indicators are available that change color as the pH is increased.
- the pH of the second composition should be less than about 6.5. More particularly, the second composition can have a pH that is consistent with mammalian tissue, which typically has a pH of about 6.5.
- the pH of the second composition should be from 4.0 to 6.5, and particularly from about 4.5 to about 6.0.
- the pH of the second composition will increase if the urea is being converted into ammonia. This rise in pH will then cause the pH indicator to signify a positive reading, such as by changing color.
- the pH of the second composition should be adjusted to have a pH of from about 0.5 pH unit to about 2 pH units lower than that necessary for a color change to occur.
- pH indicators useful in the present invention include indicators that undergo a change in color over a pH range of from about 5.5 to about 9.0, and particularly from about 6.5 to about 8.5.
- Phenol red changes from a yellow color to a red color as the pH of its surroundings increase. Phenol red is also referred to as phenolsulfonphthalein.
- pH indicators that may be used in the present invention include p-nitro-phenol, bromthymol blue (dibromthymolsulfonph-thalein), neutral red (2-methyl-3-amino-6-dimethylaminophenazine), quino-line blue (cyanine), cresol red (o-cresolsulfonphthalein), matacresol purple (m-cresolsulfonphthalein), thymol blue (thymolsulfonphthalein), bromocresol purple (4,4′-(3H-2,1-benzoxathiol-3-ylidene)bis[2-bromo-6-methylphenol] S,S-dioxide), chlorophenol red, bromocresol green (4,4′-(3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromo-3-methylphenol] S,S-dioxide), and bromophenol blue (4,4′-(3H-2,
- a combination of indicators can be used, such as described in U.S. Pat. No. 5,439,801 to Jackson, which is incorporated herein by reference.
- methyl red can be combined with bromthymol blue.
- the second composition can be made up entirely of the indicator or can include other ingredients as desired.
- the indicator can be present in a gel-like material.
- the indicator can be combined with a gelling agent so that the second composition is in a semi-solid state under ambient conditions.
- the gelling agent can be agar.
- Agar is a polysaccharide complex that is extracted from agarocytes of certain algae. Agar is available from various commercial sources. For most applications, the agar or any other gelling agent used should be nonnutritive, i.e., does not support the growth of microorganisms.
- an indicator can also be combined with a pH adjuster to maintain the pH of the second composition within preset limits.
- a pH adjuster is particularly beneficial when using a pH indicator to prevent against false readings.
- the pH of the second composition should be from about 4.0 to about 6.5, when using a pH indicator.
- a suitable pH adjuster can be used to maintain the pH of the composition within this range.
- pH adjusters suitable for this test include acids and buffering agents. The use of a pH adjuster depends upon the make-up of the second composition and the requirements of the test.
- any suitable pH adjuster can be used, depending upon the requirements of the test and the second composition, including the use of acids and buffering agents such as sodium citrate, phosphate-citrate, citric acid, sulfamic acid, sodium bisulfate, sodium acetate, sodium phosphate, and potassium phosphate.
- acids and buffering agents such as sodium citrate, phosphate-citrate, citric acid, sulfamic acid, sodium bisulfate, sodium acetate, sodium phosphate, and potassium phosphate.
- Another ingredient that may be contained in the second composition is a bactericide or a bacteristat.
- the bactericide or bacteristat can be used to act as a preservative for any of the other ingredients or can be used to substantially inhibit the growth of other organisms to prevent against false readings.
- Bactericides that can be used in the present invention include sodium azide, methyl paraben (methyl p-hydroxybenzoate), and propyl paraben (propyl p-hydroxybenzoate).
- the amount of each ingredient added to the second composition will depend upon the various circumstances and the desired result.
- the indicator can also be contained in an absorbent substrate, such as a substrate made from pulp fibers including cardboard or paper.
- the second composition can be dry and relatively moisture free. When using a paper substrate, however, extra water and distilled water, may need to be added to the second composition in combination with the biopsy sample in order to provide enough moisture to activate the indicator.
- the pH of the solid gel will be between 4 and 6.5 and particularly between 4.5 and 6.0.
- Ingredient Amount Agar (Extra Pure Grade) 1.0-50.0 g Citric Acid 0.001-1.0 g Phenol Red 0.001-2.0 g Methylhydroxy Benzoate 0.01-100.0 g Distilled Water
- ingredients can be added in the following amounts.
- the distilled water is first heated to 95° C.
- the phenol red powder is added while stirring the distilled water, and the agar is added in small amounts while the mixture is maintained at 95° C.
- the citric acid and methyl paraben are then added to the mixture.
- the bulk liquid is cooled to 50° C. and dispensed in an amount of 0.2 mL into the second well of the present invention.
- the first well of the container can contain 5 to 50 mg of the first composition, and optimally 30 mg of the resulting fine powder mixture.
- crystalline extra pure urea (Merck Catalog #1.08486.5000) is mixed with silicon dioxide (Sigma Catalog #S-5631) at a weight-to-weight ratio from 1:1 to 100:1, and in one embodiment in a weight-to-weight ratio of 2:1.
- the mixture is subject to grinding until a fine powder mixture results.
- the urease testing device instead of containing two separate wells and two separate compositions, contains a single composition in a dry powdered state.
- the urease indicating composition contains dry powdered urea combined with a dry powdered indicator.
- a urease testing device generally 110 includes a single well 112 covered by a peelable plastic film 120 .
- the well 112 includes a urease indicating composition 116 , which contains a powdered mixture of urea and an indicator.
- the powdered urea contained within the well can be a urea as described above having an average particle size of less than about 0.1 mm, particularly less than about 0.05 mm, and more particularly less than about 0.01 mm.
- a dry or powdered indicator such as a pH indicator.
- any suitable dry indicator can be present in the composition, such as any of the above-described indicators.
- the amount if indicator contained within the composition will generally depend upon the particular indicator chosen. Specifically, the indicator should be present in the composition in an amount sufficient to show a color change when the composition is contacted with urease present in a biopsy sample.
- the biopsy sample is placed in the well and mixed with the powdered composition. Any moisture present in the biopsy sample can be used to activate the urea and the indicator. If necessary, however, an aqueous solution, such as distilled water, can be added with the biopsy sample. If urease is present in the biopsy sample, the urease will convert the urea into ammonia which, in turn, will cause the indicator to indicate a positive result, such as by changing color.
- aqueous solution such as distilled water
- an anti-caking agent as described above can also be contained in the dry powdered composition.
- a pH adjuster or a bactericide will most likely not be needed, although both ingredients can be contained in the composition if desired.
- a test slide according to the present invention was prepared containing the urea composition and the indicator gel composition described above.
- the indicator gel composition did not contain the methyl paraben bactericide or the citric acid pH adjuster.
- the gel composition contained the following: Ingredient Amount Extra Pure Grade Agar 1.4941 g Phenol Red 0.0110 g Distilled Water 100.00 mL
- the shelf life of the above prepared slide was then compared with the shelf life of a commercial product marketed under the name CLO-TEST by Ballard Medical/Kimberly Clark of Draper, Utah.
- the CLO-TEST product includes a urease indicator composition which contains a mixture of urea and an indicator in a gel as described in U.S. Pat. No. 4,748,113.
- the slides were affixed to a polystyrene box introduced into a chamber set at 37° C., 100% relative humidity, and 10% carbon dioxide. Photographs were taken every 24 hours for a period of 45 days, which were then assessed and given a score using the CLO-TEST Color Chart. Using color readings with scores of equal to or greater than 4 as unusable, the CLO-TEST samples were deemed unusable on day 4, while the test slides of the present invention were still viable on day 45.
- the shelf life of the test slide of the present invention was also tested with an artificial biopsy by means of a tissue sample containing deliberately introduced urease.
- the artificial biopsy sample was placed in the first well containing the powdered urea.
- the sample was coated with urea, and then placed in the second well containing the indicator gel composition. Observations of the color change of the gel revealed it was still viable for the detection of ammonia after 39 days, when the gel was checked.
- any given range presented herein is intended to include any and all lesser included ranges.
- a range of from 45-90 would also include 50-90; 45-80; 46-89 and the like.
- the range of 95% to 99.999% also includes, for example, the ranges of 96% to 99.1%, 96.3% to 99.7%, and 99.91 to 99.999%.
Abstract
Description
- Many ailments of the gastrointestinal system in humans are caused at least in part by bacteria. Such bacteria include those of the genus Campylobacter, and particularlyHelicobacter pylori. For example, Helicobacter pylori can cause bacterial infections on the mucosal surface of the gastrointestinal tract, particularly on the surface of the stomach. The chronic disorders of the gastrointestinal system that can be caused by bacteria include peptic ulcers, gastritis, and the like.
- Once a patient is showing symptoms of a gastrointestinal disorder, several tests can be used to diagnose the disorder, including the diagnosis of a possible bacterial infection. In the past, various tests have been proposed for the detection ofHelicobacter pylori. One such test that has gained wide spread popularity and has provided many advancements in the early detection of gastrointestinal disorders is disclosed in U.S. Pat. No. 4,748,113, which is incorporated herein by reference. In the '113 patent, the presence of Helicobacter pylori in a gastric sample is detected by testing for the presence of an enzyme, specifically urease, which is produced by Helicobacter pylori in large amounts.
- Urease is known to convert urea into ammonium carbonate, which then decomposes into ammonia and carbon dioxide. Consequently, in the past, one test for detecting the presence ofHelicobacter pylori included the steps of contacting a sample of gastric material with a composition containing urea and an indicator, namely a pH indicator that changes color when there is a rise in pH. If urease is present within the gastric material it breaks down the urea, which results in the formation of ammonia after further decomposition and causes the pH indicator to change color.
- The gastric material that is collected from the patient is typically a biopsy specimen that is removed from the gastric mucosa at endoscopy by means of biopsy forceps. Typically, the tissue sample is inserted into a gel that contains urea and the indicator.
- Although the above method has provided great advancements in the early detection of gastrointestinal disorders, the testing composition used to detect the presence of urease has a limited shelf life. In particular, the urea and other reagents contained within the composition can have a tendency to degrade over time. Consequently, once formulated, the testing composition should be used in a relatively short amount of time and is also typically refrigerated prior to use in order to prevent degradation.
- In view of the above, a need currently exists for an improved testing composition and associated method for the detection of bacterial infections in the gastrointestinal tract of patients. More particularly, a need exists for a composition for detecting urease in gastric samples that has a prolonged shelf life.
- The present invention is directed to further improvements in the detection of bacterial infections in the gastrointestinal tract. In one embodiment, for instance, the present invention is directed to a system for detecting the presence of urease in a gastric sample in order to indicate the presence ofHelicobacter pylori. The system includes a first composition that is maintained separate from a second composition for sequential contact with the sample. The first composition includes urea in a dried and finely powdered state. The urea is capable of being converted into ammonia when contacted with urease. The powdered urea can have a mean particle size of less than about 0.1 mm, and particularly less than about 0.05 mm. Besides urea, the first composition can also include other powder-like components, such as an anti-caking agent to prevent the fine urea from clumping or “caking”.
- The second composition, on the other hand, can contain an indicator and can be configured to indicate the presence of ammonia. For instance, the indicator can be a pH indicator that changes color when the pH of the second composition is increased to a certain level. For example, the indicator can be phenol red, which changes from yellow to red when exposed to a pH of greater than about 6.8.
- In accordance with the present invention, the gastric biopsy sample is first contacted with the first composition. The urea powder contacts and sticks to the gastric biopsy sample. Should the gastric sample contain urease, the urea is converted into ammonia.
- After contacting the first composition, the gastric material is then contacted with the second composition containing the indicator. The indicator indicates the presence of ammonia that, in turn, is a positive test for the detection of urease.
- By maintaining the first composition containing urea separate from the second composition containing an indicator, various advantages and benefits are realized. In particular, the urea remains more stable and therefore the system has an increased shelf life. Further, the gel mixture is stable during manufacture so that much larger and longer duration production runs can be made without concern for slight temperature variations during the process.
- Besides containing an indicator, the second composition can contain various other ingredients. For example, the second composition can be in a gel-like state and can contain a gel, such as agar. To maintain a low pH in the second composition within desired limits, the second composition can also contain a pH adjuster, such as an acid or buffering agent. For example, in one embodiment, the pH adjuster can maintain the pH of the second composition in a range of from about 4.5 to about 6. The second composition can also contain a bactericide, which can inhibit the growth of other organisms.
- The first and second compositions can be contained within separate containers or can be spaced apart in the same container. For example, in one embodiment, a container can be used that includes a first well and a second well. The first composition can be located in the first well, while the second composition can be located in the second well. The container can be made from plastic and can include a peelable top made from a film. The film can be substantially or completely water impermeable over the first well to prevent any moisture from contacting the urea.
- In an alternative embodiment, the present invention is directed to a system for detecting the presence of urease in a gastric sample in which the gastric sample is contacted with a single composition. In this embodiment, the composition includes urea and a dry indicator.
- The urea, which is capable of being converted into ammonia when contacted with urease, is present in a dried and finely powdered state. The urea can have a mean particle size of less than about 0.1 mm.
- The dry indicator is configured to indicate the presence of ammonia. For instance, the indicator can be a pH indicator that changes color when the pH of the composition is increased above a certain level.
- Besides urea and a dry indicator, the composition can further include an anti-caking agent and/or a bactericide.
- In this embodiment, a gastric sample is contacted with the composition. Any liquids contained in the gastric sample can be used to activate the composition. Alternatively, a liquid, such as distilled water, can be added to the composition in conjunction with the gastric sample. If urease is present in the gastric sample, the urease breaks down urea into ammonia, which in turn activates the indicator.
- The present invention is further directed to a material well suited for detecting the presence of urease in a gastric material for diagnosing gastrointestinal disorders. The material includes a composition in the form of a powder. The composition can include urea and an anti-caking agent. Optionally, the composition can further contain a dry indicator.
- Other features and advantages of the present invention will be discussed in greater detail below.
- A full and enabling disclosure of the present invention, including the best mode thereof, to one of ordinary skill in the art is set forth more particularly in the remainder of the specification, including reference to the accompanying figures, in which:
- FIG. 1 is a perspective view of one embodiment of a system for detecting urease in accordance with the present invention;
- FIG. 2 is a top view of the system illustrated in FIG. 1;
- FIG. 3 is a cross-sectional view of the system illustrated in FIG. 1; and
- FIG. 4 is a cross-sectional view of another embodiment of a urease testing device made in accordance with the present invention.
- Repeated use of reference characters in the present specification and drawings is intended to represent same or analogous features or elements of the invention.
- Reference will now be made in detail to the embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation, not limitation of the invention. In fact, it will be apparent to those of ordinary skill in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment, can be used on another embodiment to yield a still further embodiment. Thus, it is intended that the present invention covers such modifications and variations as come within the scope of the appended claims and their equivalents.
- The present invention is generally directed to a system and method for the detection of gastrointestinal disorders caused by bacterial infections. More particularly, the system and method of the present invention detect the presence of urease on a gastric biopsy sample. Urease is an enzyme known to be produced by bacteria that are harmful to the gastrointestinal tract, including bacteria such asHelicobacter pylori. Gastrointestinal disorders that can be caused by bacterial infections include chronic or atrophic gastritis, gastroenteritis, non-ulcer dyspepsia, esophageal reflux disease, gastric motility disorders, peptic ulcers including gastric and duodenal ulcers, and the like.
- In the past, in order to detect bacterial infections in the gastrointestinal tract, a biopsy sample of gastric material was first obtained. The biopsy sample was then contacted with a composition containing urea and an indicator, such as a pH indicator. If urease were present in the biopsy sample, the urease would break down and convert the urea in the composition to ammonia subsequently causing a rise in the pH of the composition. The rise in pH then caused the indicator to undergo a color change.
- As described above, however, the composition containing urea and the indicator has a relatively short shelf life due to the instability of various ingredients in the composition, including the urea. The present invention is directed to an improved test for gastrointestinal disorders caused by bacterial infections. According to the present invention, in order to improve the shelf life of systems and devices designed to detect bacterial infections in the gastrointestinal tract, a composition containing urea is separated from a composition containing an indicator. The two compositions are then sequentially contacted with a biopsy sample in order to detect the presence of urease.
- More particularly, the first composition contains urea in a finely powdered, dry state. By maintaining urea in a powdered form separate from the agar and the indicator, the urea remains more stable. Further, by maintaining the urea separate from the indicator, the handling requirements of the test system become more relaxed. For instance, by maintaining both compositions separate, there is no need to refrigerate the compositions prior to use or during shipping.
- By maintaining the urea separate from the indicator composition, the process conditions for manufacturing the indicator composition also become relaxed. In particular, the indicator composition, such as an indicator gel, is much more stable during manufacture, allowing larger batches to be produced that are not sensitive to ingredients contained within the composition and to temperature variations.
- Although the system of the present invention for detecting urease can come in many forms, for purposes of explanation FIGS.1-3 illustrate one exemplary embodiment of a device for detecting urease in biopsy samples in accordance with the present invention. As shown, the testing device in this embodiment includes a
single container 10 defining afirst well 12 and asecond well 14. Contained in thefirst well 12 is afirst composition 16 containing urea, such as urea in a finely powdered state with or without an anti-caking agent. - In the
second well 14, on the other hand, is asecond composition 18 containing an indicator. The indicator is configured to detect the presence of ammonia. - In this embodiment, the
device 10 further includes a removable top 20 that covers thefirst well 12 and thesecond well 14. For example, the top 20 can be made from a plastic film. The top 20 is provided in order to prevent thefirst composition 16 or thesecond composition 18 from spilling or becoming contaminated prior to use. - In order to protect the powdered urea, the
film top 20 can be made liquid impermeable at a location over thefirst well 12. In particular, theentire film top 20 can be liquid impermeable or, alternatively, aseparate membrane 22 as shown in FIG. 1 can be placed over thefirst well 12 that is liquid impermeable. - Besides or in addition to making the
top film 20 liquid impermeable, themembrane 22 can also be used to prevent urea particles from sticking to the film top when the film top is removed. - In order to perform a urease test using the device shown in FIG. 1, a biopsy sample is first taken from the lining of the gastrointestinal tract of a patient, such as from the lining of the stomach. The biopsy sample can be taken at endoscopy using biopsy forceps. The
top film 20 is peeled back to expose thefirst composition 16 in thefirst well 12. The biopsy sample is then contacted with the first composition causing the urea powder to stick to the sample. For example, the biopsy sample can be rolled in the first composition much like the process of “flouring” a food product prior to cooking. - Once the first composition has coated the biopsy sample, the sample is then contacted with the
second composition 18 containing an indicator located in thesecond well 14. Once contacted with the second composition, the powdered urea on the surface of the biopsy sample is moistened and activated by the second composition. Once moistened, the urea powder becomes available in greater amounts to any urease enzyme present in the biopsy sample. If present, the urease converts the urea into the unstable ammonium bicarbonate, which further decomposes into ammonia and carbon dioxide. The indicator present in the second composition indicates the presence of ammonia to signify a positive test for urease. For example, in one embodiment the indicator can be a pH indicator that changes color when the pH of its environment is increased. - Besides being contained within a single container as shown in FIG. 1, however, it should be understood that the first and second compositions of the present invention can be maintained in any suitable separated state prior to testing. In this regard, the first composition and the second composition can be maintained in separate containers if desired.
- The ingredients that can be contained in the first composition and the second composition in accordance with the present invention will now be described in greater detail. As described above, the first composition is generally a dry or moisture-free composition containing urea in a powdered state. Urea has the chemical formula H2NCONH2 and is a naturally occurring product of protein metabolism. When contacted with urease, urea hydrolyzes to form unstable ammonium bicarbonate, which further decomposes into ammonia and carbon dioxide.
- Urea in a powdered state for use in the present invention is available from various commercial sources. The particle size of the urea contained in the first composition is generally not critical although smaller particle sizes work more efficiently. In this regard, if desired, the urea can be ground to have a mean particle size of less than about 0.1 mm, particularly less than 0.05 mm, and more particularly less than about 0.01 mm. It should be understood, however, that even smaller particle sizes may be used. For example, in one embodiment, the urea particles can have a mean particle size of less than 3 microns, and particularly less than 1 micron. By reducing the particle size, more surface area of urea is available for reaction with urease and the urea will better stick to the biopsy sample.
- When using relatively smaller particles, the urea particles can have a particle size distribution such that no particles present have a size greater than about 100 microns, particularly no greater than about 10 microns, and more particularly no greater than about 5 microns. The particle size of the urea can be determined using any suitable method, such as by using transmission electron microscopy (TEM). When using transmission electron microscopy, the average diameter of each particle is measured, followed by calculating the mean diameter of the urea particles in a particular group. The average diameter of each particle can be calculated by taking the average of the smallest diameter of the particle and the largest diameter of the particle. Besides transmission electron microscopy, light scattering can also be used to determine particle sizes. The mean particle size of the urea particles in a particular group is calculated by adding the sizes of the particles together and dividing by the number of particles.
- Besides containing urea, the first composition can also contain various other dry additives. For example, in one embodiment, if desired, an anti-caking agent can also be contained within the first composition. The anti-caking agent will prevent the fine urea powder from clumping or “caking”. Any suitable anti-caking agent can be used in the present invention. For example, in one embodiment, fine silicon dioxide or fine sodium alumino silicate powder can be contained in the first composition. The weight per weight (w/w) ratio of urea/silicon dioxide contained in the first composition can be any ratio from 1/1 to 100/1. The particle size of the anti-caking agent can vary depending upon the particular application. For instance, in one embodiment, the particle size of the anti-caking agent is no greater than the particle size of the urea.
- The second composition, which is maintained separate from the first composition, contains an indicator for indicating the presence of ammonia. In general, any suitable indicator can be present in the second composition. In one embodiment, a pH indicator can be used that indicates a change in pH. For example, various pH indicators are available that change color as the pH is increased.
- In general, when using a pH indicator, the pH of the second composition should be less than about 6.5. More particularly, the second composition can have a pH that is consistent with mammalian tissue, which typically has a pH of about 6.5.
- In this regard, the pH of the second composition should be from 4.0 to 6.5, and particularly from about 4.5 to about 6.0. In this manner, when the second composition is contacted with the biopsy sample containing urea, the pH of the second composition will increase if the urea is being converted into ammonia. This rise in pH will then cause the pH indicator to signify a positive reading, such as by changing color.
- The pH of the second composition should be adjusted to have a pH of from about 0.5 pH unit to about 2 pH units lower than that necessary for a color change to occur.
- Consequently, when using a pH indicator, the indicator should undergo a color change or otherwise signify a positive reading when the pH of the second composition rises above neutral, and particularly above about 7.5. pH indicators useful in the present invention include indicators that undergo a change in color over a pH range of from about 5.5 to about 9.0, and particularly from about 6.5 to about 8.5.
- One particular pH indicator that can be used in the present invention is phenol red. Phenol red changes from a yellow color to a red color as the pH of its surroundings increase. Phenol red is also referred to as phenolsulfonphthalein.
- Other pH indicators that may be used in the present invention include p-nitro-phenol, bromthymol blue (dibromthymolsulfonph-thalein), neutral red (2-methyl-3-amino-6-dimethylaminophenazine), quino-line blue (cyanine), cresol red (o-cresolsulfonphthalein), matacresol purple (m-cresolsulfonphthalein), thymol blue (thymolsulfonphthalein), bromocresol purple (4,4′-(3H-2,1-benzoxathiol-3-ylidene)bis[2-bromo-6-methylphenol] S,S-dioxide), chlorophenol red, bromocresol green (4,4′-(3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromo-3-methylphenol] S,S-dioxide), and bromophenol blue (4,4′-(3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide).
- In one embodiment, a combination of indicators can be used, such as described in U.S. Pat. No. 5,439,801 to Jackson, which is incorporated herein by reference. For example, in one embodiment, methyl red can be combined with bromthymol blue.
- The second composition can be made up entirely of the indicator or can include other ingredients as desired. For example, in one embodiment, the indicator can be present in a gel-like material. In this regard, the indicator can be combined with a gelling agent so that the second composition is in a semi-solid state under ambient conditions.
- In one embodiment, the gelling agent can be agar. Agar is a polysaccharide complex that is extracted from agarocytes of certain algae. Agar is available from various commercial sources. For most applications, the agar or any other gelling agent used should be nonnutritive, i.e., does not support the growth of microorganisms.
- Besides, or in addition to, a gelling agent, an indicator can also be combined with a pH adjuster to maintain the pH of the second composition within preset limits. The addition of a pH adjuster is particularly beneficial when using a pH indicator to prevent against false readings. For example, as discussed above, the pH of the second composition should be from about 4.0 to about 6.5, when using a pH indicator. A suitable pH adjuster can be used to maintain the pH of the composition within this range. pH adjusters suitable for this test include acids and buffering agents. The use of a pH adjuster depends upon the make-up of the second composition and the requirements of the test. For example, reduction of the amount of buffer in the second composition leads to a much faster reaction and a faster change in colors by the indicator, with the most rapid reaction rate occurring in the absence of a buffering agent, as compared to the reaction rate when using a large amount of a buffering agent. Thus, if a high reaction rate is required, the use of buffering agents as pH adjusters should be limited.
- In general, any suitable pH adjuster can be used, depending upon the requirements of the test and the second composition, including the use of acids and buffering agents such as sodium citrate, phosphate-citrate, citric acid, sulfamic acid, sodium bisulfate, sodium acetate, sodium phosphate, and potassium phosphate.
- Another ingredient that may be contained in the second composition is a bactericide or a bacteristat. The bactericide or bacteristat can be used to act as a preservative for any of the other ingredients or can be used to substantially inhibit the growth of other organisms to prevent against false readings. Bactericides that can be used in the present invention include sodium azide, methyl paraben (methyl p-hydroxybenzoate), and propyl paraben (propyl p-hydroxybenzoate).
- The amount of each ingredient added to the second composition will depend upon the various circumstances and the desired result. Besides maintaining the indicator as a liquid or in a gel state, the indicator can also be contained in an absorbent substrate, such as a substrate made from pulp fibers including cardboard or paper. In this embodiment, the second composition can be dry and relatively moisture free. When using a paper substrate, however, extra water and distilled water, may need to be added to the second composition in combination with the biopsy sample in order to provide enough moisture to activate the indicator.
- The following is an example of one formulation that can be used as the second composition in the system of the present invention. The pH of the solid gel will be between 4 and 6.5 and particularly between 4.5 and 6.0.
Ingredient Amount Agar (Extra Pure Grade) 1.0-50.0 g Citric Acid 0.001-1.0 g Phenol Red 0.001-2.0 g Methylhydroxy Benzoate 0.01-100.0 g Distilled Water - When forming a one liter batch of the above composition, the ingredients can be added in the following amounts.
Ingredient Reference Amount Agar (Extra Pure Grade) Merck Catalog #1.01615.9025 15.0 g Citric Acid Merck Catalog #1.00247.1000 0.0145 g Phenol Red Merck Catalog #1.07241.0025 0.110 g Methyl Paraben Merck Catalog #1.06757.5000 2.0 g Distilled Water — 1000 mL - In producing the above gel composition, the distilled water is first heated to 95° C. The phenol red powder is added while stirring the distilled water, and the agar is added in small amounts while the mixture is maintained at 95° C. The citric acid and methyl paraben are then added to the mixture. The bulk liquid is cooled to 50° C. and dispensed in an amount of 0.2 mL into the second well of the present invention.
- The first well of the container can contain 5 to 50 mg of the first composition, and optimally 30 mg of the resulting fine powder mixture. In the preparation of the urea mixture of the first composition for use in the first well, crystalline extra pure urea (Merck Catalog #1.08486.5000) is mixed with silicon dioxide (Sigma Catalog #S-5631) at a weight-to-weight ratio from 1:1 to 100:1, and in one embodiment in a weight-to-weight ratio of 2:1. The mixture is subject to grinding until a fine powder mixture results.
- Another embodiment of the present invention is illustrated in FIG. 4. In this embodiment, instead of containing two separate wells and two separate compositions, the urease testing device contains a single composition in a dry powdered state. Specifically, in this embodiment, the urease indicating composition contains dry powdered urea combined with a dry powdered indicator.
- For example, as shown in FIG. 4, a urease testing device generally110 includes a
single well 112 covered by apeelable plastic film 120. In accordance with the present invention, the well 112 includes aurease indicating composition 116, which contains a powdered mixture of urea and an indicator. - The powdered urea contained within the well can be a urea as described above having an average particle size of less than about 0.1 mm, particularly less than about 0.05 mm, and more particularly less than about 0.01 mm. Combined with the powdered urea is a dry or powdered indicator, such as a pH indicator. In general, any suitable dry indicator can be present in the composition, such as any of the above-described indicators. The amount if indicator contained within the composition will generally depend upon the particular indicator chosen. Specifically, the indicator should be present in the composition in an amount sufficient to show a color change when the composition is contacted with urease present in a biopsy sample.
- In this embodiment, the biopsy sample is placed in the well and mixed with the powdered composition. Any moisture present in the biopsy sample can be used to activate the urea and the indicator. If necessary, however, an aqueous solution, such as distilled water, can be added with the biopsy sample. If urease is present in the biopsy sample, the urease will convert the urea into ammonia which, in turn, will cause the indicator to indicate a positive result, such as by changing color.
- If desired, an anti-caking agent as described above can also be contained in the dry powdered composition. In this embodiment, however, a pH adjuster or a bactericide will most likely not be needed, although both ingredients can be contained in the composition if desired.
- The following example was performed in order to demonstrate the stability of a urease testing device made in accordance with the present invention.
- A test slide according to the present invention was prepared containing the urea composition and the indicator gel composition described above. The indicator gel composition, however, did not contain the methyl paraben bactericide or the citric acid pH adjuster.
- Specifically, the gel composition contained the following:
Ingredient Amount Extra Pure Grade Agar 1.4941 g Phenol Red 0.0110 g Distilled Water 100.00 mL - The shelf life of the above prepared slide was then compared with the shelf life of a commercial product marketed under the name CLO-TEST by Ballard Medical/Kimberly Clark of Draper, Utah. The CLO-TEST product includes a urease indicator composition which contains a mixture of urea and an indicator in a gel as described in U.S. Pat. No. 4,748,113.
- Three test slides made according to the present invention were compared with three samples of the CLO-TEST product. A standardized CLO-TEST Color Chart developed prior to the experiment was used to assign numerical scores to the color of the samples during the experiment.
- The slides were affixed to a polystyrene box introduced into a chamber set at 37° C., 100% relative humidity, and 10% carbon dioxide. Photographs were taken every 24 hours for a period of 45 days, which were then assessed and given a score using the CLO-TEST Color Chart. Using color readings with scores of equal to or greater than 4 as unusable, the CLO-TEST samples were deemed unusable on day 4, while the test slides of the present invention were still viable on day 45.
- The shelf life of the test slide of the present invention was also tested with an artificial biopsy by means of a tissue sample containing deliberately introduced urease. The artificial biopsy sample was placed in the first well containing the powdered urea. The sample was coated with urea, and then placed in the second well containing the indicator gel composition. Observations of the color change of the gel revealed it was still viable for the detection of ammonia after 39 days, when the gel was checked.
- It should be noted that any given range presented herein is intended to include any and all lesser included ranges. For example, a range of from 45-90 would also include 50-90; 45-80; 46-89 and the like. Thus, the range of 95% to 99.999% also includes, for example, the ranges of 96% to 99.1%, 96.3% to 99.7%, and 99.91 to 99.999%.
Claims (18)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/977,556 US7008777B2 (en) | 2001-10-15 | 2001-10-15 | System for the detection of urease and method for using same |
AU2002327667A AU2002327667B2 (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
MXPA04003083A MXPA04003083A (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same. |
CA2462649A CA2462649C (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
JP2003536746A JP2005536980A (en) | 2001-10-15 | 2002-09-18 | Urease detection system and use thereof |
PCT/US2002/029814 WO2003034061A2 (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
BR0213058-0A BR0213058A (en) | 2001-10-15 | 2002-09-18 | System for detecting urease and process for using it |
KR10-2004-7004736A KR20040047878A (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
AT08000375T ATE462138T1 (en) | 2001-10-15 | 2002-09-18 | UREASE DETECTION SYSTEM AND METHOD FOR USING THE SAME |
DE60227971T DE60227971D1 (en) | 2001-10-15 | 2002-09-18 | DEVICE AND METHOD FOR DETECTING UREASE |
EP08000375A EP1918712B1 (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
AT02763668T ATE403155T1 (en) | 2001-10-15 | 2002-09-18 | DEVICE AND METHOD FOR DETECTING UREASE |
DE60235779T DE60235779D1 (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method of using the same |
EP02763668A EP1438587B1 (en) | 2001-10-15 | 2002-09-18 | System for the detection of urease and method for using same |
ARP020103838A AR036801A1 (en) | 2001-10-15 | 2002-10-11 | A METHOD FOR DETECTING THE PRESENCE OF UREASA IN A GASTROINTESTINAL SYSTEM, THE SYSTEM OBTAINED AND A SUITABLE MATERIAL FOR SUCH DETECTION |
NO20041366A NO20041366L (en) | 2001-10-15 | 2004-04-01 | Urease detection system and method for using it |
AU2009200581A AU2009200581A1 (en) | 2001-10-15 | 2009-02-13 | System for the detection of urease and method for using same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/977,556 US7008777B2 (en) | 2001-10-15 | 2001-10-15 | System for the detection of urease and method for using same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030082664A1 true US20030082664A1 (en) | 2003-05-01 |
US7008777B2 US7008777B2 (en) | 2006-03-07 |
Family
ID=25525271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/977,556 Expired - Fee Related US7008777B2 (en) | 2001-10-15 | 2001-10-15 | System for the detection of urease and method for using same |
Country Status (1)
Country | Link |
---|---|
US (1) | US7008777B2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087398B2 (en) * | 2001-10-15 | 2006-08-08 | Marshall Barry J | Method for detecting urease |
US20100028937A1 (en) * | 2008-02-12 | 2010-02-04 | Chia-Chen Liu | Test strip for detecting gastric problems and detecting method thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE495267T1 (en) * | 2007-03-13 | 2011-01-15 | Abs Advanced Biomedical Systems Srl | DIAGNOSTIC METHOD FOR DETECTING HELICOBACTER PYLORI |
US8888720B2 (en) | 2010-04-02 | 2014-11-18 | Stanford P. Hudson | Great toe dorsiflexion detection |
Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1521689A (en) * | 1922-07-10 | 1925-01-06 | Gustave A King | Tweezers |
US3145086A (en) * | 1960-05-05 | 1964-08-18 | Miles Lab | Diagnostic composition |
US3247051A (en) * | 1962-12-13 | 1966-04-19 | Metal & Thermit Corp | Method of protection against growth of microorganisms with organo-bismuth compound |
US3395082A (en) * | 1964-07-20 | 1968-07-30 | Miles Lab | Test composition device and method for detecting urea in aqueous fluids |
US3411723A (en) * | 1966-01-27 | 1968-11-19 | Joseph D. Kohn | Disposable spatula |
US3461036A (en) * | 1964-07-20 | 1969-08-12 | Jeanne T Harvill | Test composition,device and method for detecting urea in aqueous fluids |
US3653389A (en) * | 1970-01-19 | 1972-04-04 | Amp Inc | Disposable forceps |
US3828765A (en) * | 1971-11-24 | 1974-08-13 | Medical Testing Syst Inc | Genitourinary test instrument |
US3852413A (en) * | 1970-07-06 | 1974-12-03 | Searle & Co | Labelled sulfated amylopectins and method of determining abnormal gastrointestinal mucosa |
US3873269A (en) * | 1972-10-11 | 1975-03-25 | Merck Patent Gmbh | Indicator for the determination of urea |
US3876502A (en) * | 1971-10-20 | 1975-04-08 | Mallinckodt Inc | Reagent formulations for assaying urea nitrogen in biological specimens and methods of preparing and using same |
US4016268A (en) * | 1975-10-06 | 1977-04-05 | Morton-Norwich Products, Inc. | Method of combatting gastric ulceration |
US4016865A (en) * | 1975-09-17 | 1977-04-12 | Fredricks Richard N | Cervical-vaginal spatula |
US4027658A (en) * | 1975-12-01 | 1977-06-07 | Manly Ernest Marshall | Instrument for taking samples |
US4101382A (en) * | 1974-10-31 | 1978-07-18 | Moon Ki Chang | Novel reagent and method for the determination of urea in biological fluids |
USD249772S (en) * | 1976-07-23 | 1978-10-03 | Amiot Anne T | Sculpturing tool |
US4132502A (en) * | 1976-06-10 | 1979-01-02 | Bayer Aktiengesellschaft | Spatula for mixing plastic substances |
US4153685A (en) * | 1968-11-23 | 1979-05-08 | Schering Corporation | Bismuth complex preparations |
US4160505A (en) * | 1977-12-19 | 1979-07-10 | Will Ross Inc. | Catheterization tray |
US4226328A (en) * | 1979-04-09 | 1980-10-07 | Baxter Travenol Laboratories, Inc. | Catheterization package |
US4282316A (en) * | 1979-09-11 | 1981-08-04 | Modrovich Ivan Endre | Stabilized enzymic solutions for determining urea |
US4293074A (en) * | 1979-12-04 | 1981-10-06 | Dunsky Joel L | Root canal equipment packaging |
USD266434S (en) * | 1980-10-03 | 1982-10-05 | Kowalski Chester W | Clay molding tool |
USD271370S (en) * | 1981-05-26 | 1983-11-15 | Louis San Antonio | Ceramic clean-up trim tool |
US4548805A (en) * | 1983-12-27 | 1985-10-22 | Sack David A | Non-invasive test for gastric acid |
US4581221A (en) * | 1983-08-29 | 1986-04-08 | Medi Nuclear Corporation, Inc. | Ulcer detection |
US4585623A (en) * | 1984-02-27 | 1986-04-29 | Allelix Inc. | Device for performing quantitative chemical and immunochemical assays |
US4620548A (en) * | 1980-04-21 | 1986-11-04 | Accupap, Inc. | Pap smear T-zone sampler |
US4641662A (en) * | 1984-09-28 | 1987-02-10 | Jaicks John R | Endocervical curette system |
USD288716S (en) * | 1984-08-08 | 1987-03-10 | Tambrands Inc. | Diagnostic test kit |
US4690801A (en) * | 1986-06-03 | 1987-09-01 | Allelix Inc. | Device for performing enzyme immunoassays |
US4736850A (en) * | 1986-10-17 | 1988-04-12 | W. L. Gore & Associates, Inc. | Endothelial cell harvesting kit |
US4748113A (en) * | 1985-06-13 | 1988-05-31 | Marshall Barry J | Compositions and methods for the diagnosis of gastrointestinal disorders involving urease |
US4777947A (en) * | 1986-09-23 | 1988-10-18 | Roland J. Zwick, Inc. | Endocervical curette |
US4830010A (en) * | 1986-04-04 | 1989-05-16 | Marshall Barry J | Methods for the diagnosis of gastrointestinal disorders |
USD301371S (en) * | 1986-07-10 | 1989-05-30 | George Kaprelian | Dental bracket placement instrument |
US4923801A (en) * | 1987-04-13 | 1990-05-08 | The University Of Virginia Alumni Patents Foundation | Compositions and methods for the enrichment and isolation of Campylobacter pylori and related organisms from biological specimens and the environment |
USD327322S (en) * | 1990-03-20 | 1992-06-23 | Brewer Jr John M | Curette |
USD328347S (en) * | 1990-10-01 | 1992-07-28 | Santora Harry J | Dental instrument for sculpting |
USD331800S (en) * | 1990-08-13 | 1992-12-15 | Johnny Han | Forceps |
US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
US5258178A (en) * | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
US5304540A (en) * | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
US5439801A (en) * | 1994-02-14 | 1995-08-08 | Chek-Med Systems, Inc. | Test composition for the rapid detection of helicobacter pylori in gastric biopsy tissue |
US5479019A (en) * | 1993-07-13 | 1995-12-26 | Mic Medical Instrument Corporation | Apparatus for determining the 13 CO2 /12 CO2 ratio of concentrations in a gas sample |
US5498528A (en) * | 1994-06-10 | 1996-03-12 | King; Wing | Detection of helicobacter pylori |
USD368520S (en) * | 1994-12-14 | 1996-04-02 | Brewer Jr John M | Curette |
US5593851A (en) * | 1994-04-01 | 1997-01-14 | Chek-Med Systems, Inc. | Test kid for the rapid detection of helicobacter pylori in gastric biopsy tissue |
US5601848A (en) * | 1985-06-13 | 1997-02-11 | The Procter & Gamble Company | Methods for the treatment of gastrointestinal disorders |
US5679570A (en) * | 1992-12-08 | 1997-10-21 | Heckenmuller; Harald | Device for performing urease tests on combined antrum/corpus biopsies to diagnose gastrointestinal illnesses |
US5702911A (en) * | 1996-08-15 | 1997-12-30 | Chek-Med Systems, Inc. | Diagnostic test composition |
USD390659S (en) * | 1997-03-31 | 1998-02-10 | Bristol-Myers Squibb Company | Bone cement scoop |
USD393312S (en) * | 1997-06-12 | 1998-04-07 | Bionix Development Corporation | Ear curette |
US5738110A (en) * | 1996-05-29 | 1998-04-14 | Beal; Charles B. | Device for the diagnosis of certain gastrointestinal pathogens |
US5782951A (en) * | 1997-02-20 | 1998-07-21 | Western Industrial Clay Products, Inc. | Particulate urea with finely divided inorganic material incorporated for hardness nonfriability and anti-caking |
US5846751A (en) * | 1990-12-04 | 1998-12-08 | Quidel Corporation | Test kits and methods for detecting H. pylori |
US5854013A (en) * | 1995-09-14 | 1998-12-29 | Infectech, Inc. | Method of determining the presence or absence of a nonparaffinophilic microorganism in a specimen |
US5893853A (en) * | 1997-01-31 | 1999-04-13 | Arnold; James E. | Method for transplanting grafts of skin having at least one hair |
USD415275S (en) * | 1997-06-12 | 1999-10-12 | Bionix Development Corporation | Ear curette |
US5997567A (en) * | 1998-03-10 | 1999-12-07 | Cangelosi; Joseph | Forked suture forceps |
USD419238S (en) * | 1998-12-03 | 2000-01-18 | Denbur, Inc. | Disposable dental applicator handle |
USD420133S (en) * | 1997-06-12 | 2000-02-01 | Bionix Development Corporation | Ear curette |
US6039955A (en) * | 1996-07-01 | 2000-03-21 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making the same |
US6048735A (en) * | 1996-12-05 | 2000-04-11 | Idego Aps | Sensor laminates and multi-sectioned fluid delivery devices for detecting by immunoassay target molecules in biological fluids |
USD423669S (en) * | 1999-01-08 | 2000-04-25 | Bionix Development Corporation | Curette |
US6060241A (en) * | 1996-04-05 | 2000-05-09 | Kieta Holding Sa | Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases |
US6068985A (en) * | 1992-04-29 | 2000-05-30 | Provalis Uk Limited | In vitro test for Helicobacter pylori |
USD428489S (en) * | 1998-09-09 | 2000-07-18 | Bionix Development Corp. | Ear curette |
USD428991S (en) * | 1908-09-30 | 2000-08-01 | Harwill Industries (Pty) Ltd. | Cervical spatula |
US6113875A (en) * | 1994-11-02 | 2000-09-05 | Diabact Ab | Diagnostic preparation for detection of helicobacter pylori |
US6156346A (en) * | 1997-01-29 | 2000-12-05 | Johns Hopkins University | Urease-responsive delivery systems for diagnostic and therapeutic applications |
USD435293S (en) * | 2000-01-13 | 2000-12-19 | Brian Tang | Dental tool |
US6165736A (en) * | 1998-07-28 | 2000-12-26 | The Nemours Foundation | Method of detecting bacterial infection |
US6172215B1 (en) * | 1996-07-24 | 2001-01-09 | Fuso Pharmaceutical Industries, Ltd. | Probes for detecting and identifying Helicobacter pylori |
US6171811B1 (en) * | 1996-11-12 | 2001-01-09 | Isomed, S.L. | Method and kit for detecting Helicobacter pylori |
US6187556B1 (en) * | 1998-04-03 | 2001-02-13 | Jong-Hwa Lee | Composition, kit, and method for detecting Helicobacter pylori in biopsy |
USD438979S1 (en) * | 1999-09-28 | 2001-03-13 | Bel-Art Products, Inc. | Sampling arrangement |
US6228605B1 (en) * | 1993-10-28 | 2001-05-08 | Barry J. Marshall | Detection of helicobacter pylori in the stomach |
USD445503S1 (en) * | 1998-09-09 | 2001-07-24 | Bionix Development Corporation | Ear curette |
US6270514B1 (en) * | 2000-01-10 | 2001-08-07 | Surgical Concepts, Inc. | Sensitive adjustment forceps apparatus |
USD447237S1 (en) * | 1999-06-21 | 2001-08-28 | Bionix Development Corporation | Curette |
USD452936S1 (en) * | 2000-03-28 | 2002-01-08 | Ideal-Tek S.A. | Precision tweezers |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE857426C (en) | 1948-10-02 | 1952-11-27 | Otto Dr Hansen | Process for greasing tanned skins |
FR1472956A (en) | 1964-07-20 | 1967-06-01 | ||
FR5877M (en) | 1966-07-22 | 1968-03-18 | ||
ZA74385B (en) | 1974-01-18 | 1975-08-27 | Gist Brocades Nv | Pharmaceutical compositions |
FI57128C (en) | 1978-11-21 | 1980-06-10 | Orion Yhtymae Oy | SAETT ATT IDENTIFIED MICROORGANISM |
JPH0321160B2 (en) | 1979-05-02 | 1991-03-22 | Nat Res Dev | |
EP0065541B1 (en) | 1980-11-13 | 1985-09-18 | Harry H. Leveen | Intraocular lens forceps |
US4851209A (en) | 1982-11-12 | 1989-07-25 | The Regents Of The University Of California | Diagnostic procedures using radio labeled sucralfate and derivatives or precursors thereof |
US4932957A (en) | 1986-09-23 | 1990-06-12 | Ronald J. Zwick, Inc. | Endocervical curette |
US4803983A (en) | 1987-03-23 | 1989-02-14 | Siegel Irwin M | Muscle biopsy clamp |
US4829006A (en) | 1988-02-01 | 1989-05-09 | Difco Laboratories | Centrifugation vial and cluster tray |
ES1007905Y (en) | 1988-10-10 | 1989-09-01 | Garrido-Lestache Y Cabrera Antonio | LINGUAL DEPRESSOR FOR USE IN PEDIATRICS. |
US5182191A (en) | 1988-10-14 | 1993-01-26 | Pacific Biotech, Inc. | Occult blood sampling device and assay |
EP0369292A1 (en) * | 1988-11-15 | 1990-05-23 | Röhm Pharma GmbH | Diagnostic unit dose for the determination of urease |
US4955971A (en) | 1989-04-10 | 1990-09-11 | Goulter Victor H | Multi-purpose tool utilizing arms with parallelogram coupling at proximal ends |
US4947861A (en) | 1989-05-01 | 1990-08-14 | Hamilton Lyle H | Noninvasive diagnosis of gastritis and duodenitis |
US5116346A (en) | 1989-10-27 | 1992-05-26 | Acuderm, Inc. | Disposable dermal curette |
FR2654436A1 (en) | 1989-11-14 | 1991-05-17 | Nantes Ctre Hospitalier Rgl Un | Process for assaying urea and urease, and box of reagents necessary for carrying out this process |
US5238651A (en) | 1990-07-23 | 1993-08-24 | New York University | Gel plates, equipment and kits for combined electrophoretic-immunoelectrophoretic analysis |
US5380492A (en) | 1990-12-18 | 1995-01-10 | Seymour; Eugene H. | Sampling device and sample adequacy system |
US5149506A (en) | 1991-08-09 | 1992-09-22 | Sage Products, Inc. | Stool collection and transport device |
JPH07500185A (en) | 1991-10-09 | 1995-01-05 | ハワイ ケムテクト インターナショナル | Field kit for testing analytes |
US5228201A (en) | 1992-03-05 | 1993-07-20 | Atkins Norman J | Combination kitchen utensil |
US5348023A (en) | 1992-04-16 | 1994-09-20 | Mclucas Bruce | Curetting instrument and method |
US5709838A (en) | 1992-06-01 | 1998-01-20 | Nik Public Safety, Inc. | Single use sampling device |
US5339955A (en) | 1992-12-18 | 1994-08-23 | Devon Industries, Inc. | Instrument tray with instrument supports |
US5366893A (en) | 1993-01-13 | 1994-11-22 | Becton, Dickinson And Company | Culture vessel |
US5449071A (en) | 1993-10-28 | 1995-09-12 | Levy; Abner | Tray for medical specimen collection kit |
US5624554A (en) | 1993-11-22 | 1997-04-29 | Biomedical Polymers, Inc. | Collection and transfer device |
US5431884A (en) | 1994-02-22 | 1995-07-11 | Sage Products, Inc. | Specimen transporting and processing system |
US5542419A (en) | 1994-02-28 | 1996-08-06 | Boston University | Noninvasive method to detect gastric Helicobacter pylori |
JPH07289289A (en) | 1994-04-27 | 1995-11-07 | Gastec:Kk | Method for simply performing test for helicobacter pylori and instrument for performing test |
US5501597A (en) | 1994-04-29 | 1996-03-26 | Minnesota Prophy Power, Inc. | Dental instrument with gripping handle and method for manufacturing same |
US5682665A (en) | 1994-10-11 | 1997-11-04 | Svanberg; Gunnar K. | Method for manufacturing a dental curette |
US5494162A (en) | 1994-11-18 | 1996-02-27 | Trebay Medical Corporation | Package and method for delivering a medical implant |
EP0721898A1 (en) | 1995-01-11 | 1996-07-17 | Erwin S. Neumeyer | Storage system and container therefor |
GB2307987A (en) | 1995-12-06 | 1997-06-11 | Univ Manchester | Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto |
SE9600071D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE9601659D0 (en) | 1996-04-30 | 1996-04-30 | Diabact Ab | Diagnostic drug preparation |
US5848975A (en) | 1996-07-01 | 1998-12-15 | St. Vincent's Medical Center Of Richmond | Breath test for helicobacter pylori |
AU3785797A (en) | 1996-08-13 | 1998-03-06 | Kyowa Hakko Kogyo Co. Ltd. | Isotopic urea tablets |
US5722422A (en) | 1997-02-12 | 1998-03-03 | Symbiosis Corporation | Endoscopic biopsy forceps handle with removable sample removal pick |
US6067989A (en) | 1997-02-26 | 2000-05-30 | Oridion Medical, Ltd. | Breath test for the diagnosis of Helicobacter pylori infection in the gastrointestinal tract |
US5989840A (en) | 1997-05-29 | 1999-11-23 | Americare International Diagnostics, Inc. | Estimation of active infection by heliobacter pylori |
US6258327B1 (en) | 1998-04-03 | 2001-07-10 | E. Terry Tatum | Biopsy specimen collection device |
US6291234B1 (en) | 1998-08-25 | 2001-09-18 | Morphometrix Technologies Inc. | Method and apparatus for transferring a biological specimen to a cellular suspension |
US6116426A (en) | 1999-10-11 | 2000-09-12 | Slonim; Charles B. | Emergency eye kit |
US6309818B1 (en) | 2000-02-01 | 2001-10-30 | The United States Of America As Represented By The Department Of Health & Human Services | Scratch wound assay device |
AU1904201A (en) | 2000-03-02 | 2001-09-12 | Traian Baltateanu | Blisterpack for single use, with applicator and application product |
-
2001
- 2001-10-15 US US09/977,556 patent/US7008777B2/en not_active Expired - Fee Related
Patent Citations (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USD428991S (en) * | 1908-09-30 | 2000-08-01 | Harwill Industries (Pty) Ltd. | Cervical spatula |
US1521689A (en) * | 1922-07-10 | 1925-01-06 | Gustave A King | Tweezers |
US3145086A (en) * | 1960-05-05 | 1964-08-18 | Miles Lab | Diagnostic composition |
US3247051A (en) * | 1962-12-13 | 1966-04-19 | Metal & Thermit Corp | Method of protection against growth of microorganisms with organo-bismuth compound |
US3395082A (en) * | 1964-07-20 | 1968-07-30 | Miles Lab | Test composition device and method for detecting urea in aqueous fluids |
US3461036A (en) * | 1964-07-20 | 1969-08-12 | Jeanne T Harvill | Test composition,device and method for detecting urea in aqueous fluids |
US3411723A (en) * | 1966-01-27 | 1968-11-19 | Joseph D. Kohn | Disposable spatula |
US4153685A (en) * | 1968-11-23 | 1979-05-08 | Schering Corporation | Bismuth complex preparations |
US3653389A (en) * | 1970-01-19 | 1972-04-04 | Amp Inc | Disposable forceps |
US3852413A (en) * | 1970-07-06 | 1974-12-03 | Searle & Co | Labelled sulfated amylopectins and method of determining abnormal gastrointestinal mucosa |
US3876502A (en) * | 1971-10-20 | 1975-04-08 | Mallinckodt Inc | Reagent formulations for assaying urea nitrogen in biological specimens and methods of preparing and using same |
US3828765A (en) * | 1971-11-24 | 1974-08-13 | Medical Testing Syst Inc | Genitourinary test instrument |
US3873269A (en) * | 1972-10-11 | 1975-03-25 | Merck Patent Gmbh | Indicator for the determination of urea |
US4101382A (en) * | 1974-10-31 | 1978-07-18 | Moon Ki Chang | Novel reagent and method for the determination of urea in biological fluids |
US4016865A (en) * | 1975-09-17 | 1977-04-12 | Fredricks Richard N | Cervical-vaginal spatula |
US4016268A (en) * | 1975-10-06 | 1977-04-05 | Morton-Norwich Products, Inc. | Method of combatting gastric ulceration |
US4027658A (en) * | 1975-12-01 | 1977-06-07 | Manly Ernest Marshall | Instrument for taking samples |
US4132502A (en) * | 1976-06-10 | 1979-01-02 | Bayer Aktiengesellschaft | Spatula for mixing plastic substances |
USD249772S (en) * | 1976-07-23 | 1978-10-03 | Amiot Anne T | Sculpturing tool |
US4160505A (en) * | 1977-12-19 | 1979-07-10 | Will Ross Inc. | Catheterization tray |
US4226328A (en) * | 1979-04-09 | 1980-10-07 | Baxter Travenol Laboratories, Inc. | Catheterization package |
US4282316A (en) * | 1979-09-11 | 1981-08-04 | Modrovich Ivan Endre | Stabilized enzymic solutions for determining urea |
US4293074A (en) * | 1979-12-04 | 1981-10-06 | Dunsky Joel L | Root canal equipment packaging |
US4620548A (en) * | 1980-04-21 | 1986-11-04 | Accupap, Inc. | Pap smear T-zone sampler |
USD266434S (en) * | 1980-10-03 | 1982-10-05 | Kowalski Chester W | Clay molding tool |
USD271370S (en) * | 1981-05-26 | 1983-11-15 | Louis San Antonio | Ceramic clean-up trim tool |
US4581221A (en) * | 1983-08-29 | 1986-04-08 | Medi Nuclear Corporation, Inc. | Ulcer detection |
US4548805A (en) * | 1983-12-27 | 1985-10-22 | Sack David A | Non-invasive test for gastric acid |
US4585623A (en) * | 1984-02-27 | 1986-04-29 | Allelix Inc. | Device for performing quantitative chemical and immunochemical assays |
USD288716S (en) * | 1984-08-08 | 1987-03-10 | Tambrands Inc. | Diagnostic test kit |
US4641662A (en) * | 1984-09-28 | 1987-02-10 | Jaicks John R | Endocervical curette system |
US4748113A (en) * | 1985-06-13 | 1988-05-31 | Marshall Barry J | Compositions and methods for the diagnosis of gastrointestinal disorders involving urease |
US5601848A (en) * | 1985-06-13 | 1997-02-11 | The Procter & Gamble Company | Methods for the treatment of gastrointestinal disorders |
US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
US4830010A (en) * | 1986-04-04 | 1989-05-16 | Marshall Barry J | Methods for the diagnosis of gastrointestinal disorders |
US4690801A (en) * | 1986-06-03 | 1987-09-01 | Allelix Inc. | Device for performing enzyme immunoassays |
USD301371S (en) * | 1986-07-10 | 1989-05-30 | George Kaprelian | Dental bracket placement instrument |
US4777947A (en) * | 1986-09-23 | 1988-10-18 | Roland J. Zwick, Inc. | Endocervical curette |
US4736850A (en) * | 1986-10-17 | 1988-04-12 | W. L. Gore & Associates, Inc. | Endothelial cell harvesting kit |
US4923801A (en) * | 1987-04-13 | 1990-05-08 | The University Of Virginia Alumni Patents Foundation | Compositions and methods for the enrichment and isolation of Campylobacter pylori and related organisms from biological specimens and the environment |
US5304540A (en) * | 1988-06-22 | 1994-04-19 | Applied Microbiology, Inc. | Pharmaceutical bacteriocin compositions and methods for using the same |
USD327322S (en) * | 1990-03-20 | 1992-06-23 | Brewer Jr John M | Curette |
US5258178A (en) * | 1990-07-30 | 1993-11-02 | Abbott Laboratories | Method and product for the treatment of gastric disease |
US5260057A (en) * | 1990-07-30 | 1993-11-09 | Abbott Laboratories | Method and product for the treatment of gastric disease |
USD331800S (en) * | 1990-08-13 | 1992-12-15 | Johnny Han | Forceps |
USD328347S (en) * | 1990-10-01 | 1992-07-28 | Santora Harry J | Dental instrument for sculpting |
US5846751A (en) * | 1990-12-04 | 1998-12-08 | Quidel Corporation | Test kits and methods for detecting H. pylori |
US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
US5420016A (en) * | 1992-03-24 | 1995-05-30 | Serim Research Corporation | Test device and kit for detecting helicobacter pylori |
US6068985A (en) * | 1992-04-29 | 2000-05-30 | Provalis Uk Limited | In vitro test for Helicobacter pylori |
US5679570A (en) * | 1992-12-08 | 1997-10-21 | Heckenmuller; Harald | Device for performing urease tests on combined antrum/corpus biopsies to diagnose gastrointestinal illnesses |
US5479019A (en) * | 1993-07-13 | 1995-12-26 | Mic Medical Instrument Corporation | Apparatus for determining the 13 CO2 /12 CO2 ratio of concentrations in a gas sample |
US6228605B1 (en) * | 1993-10-28 | 2001-05-08 | Barry J. Marshall | Detection of helicobacter pylori in the stomach |
US5439801A (en) * | 1994-02-14 | 1995-08-08 | Chek-Med Systems, Inc. | Test composition for the rapid detection of helicobacter pylori in gastric biopsy tissue |
US5593851A (en) * | 1994-04-01 | 1997-01-14 | Chek-Med Systems, Inc. | Test kid for the rapid detection of helicobacter pylori in gastric biopsy tissue |
US5498528A (en) * | 1994-06-10 | 1996-03-12 | King; Wing | Detection of helicobacter pylori |
US6113875A (en) * | 1994-11-02 | 2000-09-05 | Diabact Ab | Diagnostic preparation for detection of helicobacter pylori |
USD368520S (en) * | 1994-12-14 | 1996-04-02 | Brewer Jr John M | Curette |
US5854013A (en) * | 1995-09-14 | 1998-12-29 | Infectech, Inc. | Method of determining the presence or absence of a nonparaffinophilic microorganism in a specimen |
US6060241A (en) * | 1996-04-05 | 2000-05-09 | Kieta Holding Sa | Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases |
US5738110A (en) * | 1996-05-29 | 1998-04-14 | Beal; Charles B. | Device for the diagnosis of certain gastrointestinal pathogens |
US6039955A (en) * | 1996-07-01 | 2000-03-21 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making the same |
US6172215B1 (en) * | 1996-07-24 | 2001-01-09 | Fuso Pharmaceutical Industries, Ltd. | Probes for detecting and identifying Helicobacter pylori |
US5702911A (en) * | 1996-08-15 | 1997-12-30 | Chek-Med Systems, Inc. | Diagnostic test composition |
US6171811B1 (en) * | 1996-11-12 | 2001-01-09 | Isomed, S.L. | Method and kit for detecting Helicobacter pylori |
US6048735A (en) * | 1996-12-05 | 2000-04-11 | Idego Aps | Sensor laminates and multi-sectioned fluid delivery devices for detecting by immunoassay target molecules in biological fluids |
US6156346A (en) * | 1997-01-29 | 2000-12-05 | Johns Hopkins University | Urease-responsive delivery systems for diagnostic and therapeutic applications |
US5893853A (en) * | 1997-01-31 | 1999-04-13 | Arnold; James E. | Method for transplanting grafts of skin having at least one hair |
US5782951A (en) * | 1997-02-20 | 1998-07-21 | Western Industrial Clay Products, Inc. | Particulate urea with finely divided inorganic material incorporated for hardness nonfriability and anti-caking |
USD390659S (en) * | 1997-03-31 | 1998-02-10 | Bristol-Myers Squibb Company | Bone cement scoop |
USD420133S (en) * | 1997-06-12 | 2000-02-01 | Bionix Development Corporation | Ear curette |
USD415275S (en) * | 1997-06-12 | 1999-10-12 | Bionix Development Corporation | Ear curette |
USD393312S (en) * | 1997-06-12 | 1998-04-07 | Bionix Development Corporation | Ear curette |
US5997567A (en) * | 1998-03-10 | 1999-12-07 | Cangelosi; Joseph | Forked suture forceps |
US6187556B1 (en) * | 1998-04-03 | 2001-02-13 | Jong-Hwa Lee | Composition, kit, and method for detecting Helicobacter pylori in biopsy |
US6165736A (en) * | 1998-07-28 | 2000-12-26 | The Nemours Foundation | Method of detecting bacterial infection |
USD428489S (en) * | 1998-09-09 | 2000-07-18 | Bionix Development Corp. | Ear curette |
USD445503S1 (en) * | 1998-09-09 | 2001-07-24 | Bionix Development Corporation | Ear curette |
USD419238S (en) * | 1998-12-03 | 2000-01-18 | Denbur, Inc. | Disposable dental applicator handle |
USD423669S (en) * | 1999-01-08 | 2000-04-25 | Bionix Development Corporation | Curette |
USD447237S1 (en) * | 1999-06-21 | 2001-08-28 | Bionix Development Corporation | Curette |
USD438979S1 (en) * | 1999-09-28 | 2001-03-13 | Bel-Art Products, Inc. | Sampling arrangement |
US6270514B1 (en) * | 2000-01-10 | 2001-08-07 | Surgical Concepts, Inc. | Sensitive adjustment forceps apparatus |
USD435293S (en) * | 2000-01-13 | 2000-12-19 | Brian Tang | Dental tool |
USD452936S1 (en) * | 2000-03-28 | 2002-01-08 | Ideal-Tek S.A. | Precision tweezers |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087398B2 (en) * | 2001-10-15 | 2006-08-08 | Marshall Barry J | Method for detecting urease |
US20100028937A1 (en) * | 2008-02-12 | 2010-02-04 | Chia-Chen Liu | Test strip for detecting gastric problems and detecting method thereof |
Also Published As
Publication number | Publication date |
---|---|
US7008777B2 (en) | 2006-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5498528A (en) | Detection of helicobacter pylori | |
Dent et al. | Evaluation of a new selective medium for Campylobacter pylori | |
FI76379C (en) | Means and procedure for rapid diagnosis of dental caries by a non-wet procedure | |
CA2160916C (en) | Test composition for the rapid detection of helicobacter pylori in gastric biopsy tissue | |
US6929926B2 (en) | Composition for the detection of gastrointestinal disorders | |
US7087398B2 (en) | Method for detecting urease | |
US7008777B2 (en) | System for the detection of urease and method for using same | |
EP0204438B1 (en) | Compositions and methods for the detection of urease for the diagnosis of campylobacter pyloridis infection | |
US6998250B2 (en) | Method for detecting Helicobacter pylori | |
US6187556B1 (en) | Composition, kit, and method for detecting Helicobacter pylori in biopsy | |
US9410179B2 (en) | Diagnostic method for the determination of Helicobacter pylori | |
EP1918712B1 (en) | System for the detection of urease and method for using same | |
AU2002327667A1 (en) | System for the detection of urease and method for using same | |
ES2229365T3 (en) | TRIAL TEST TO DETECT GASTRIC PROBLEMS BASED ON THE PRESENCE OF UREASA. | |
US20030068656A1 (en) | Test strip for detecting gastric problems based on the presence of urease | |
JP4620172B2 (en) | Stabilization of phenyl phosphate with charcoal. | |
AU601363B2 (en) | Compositions and methods for the detection of urease for the diagnosis of gastrointestinal disorder | |
RU2124725C1 (en) | Method and composition for diagnosing gastroenteric disease | |
AU2016200608A1 (en) | Composition and apparatus for detecting urease in gastric contents | |
MXPA95004461A (en) | Test composition for the rapid detection of helicobacter pylori in a biopsiagastr tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARSHALL, BARRY J.;MENDIS, ARUNI H. W.;CHAIRMAN, SIMON;REEL/FRAME:012579/0929 Effective date: 20011015 |
|
AS | Assignment |
Owner name: KIMBERLY-CLARK WORLDWIDE, INC., WISCONSIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MARSHALL, BARRY J.;REEL/FRAME:015510/0200 Effective date: 20040621 |
|
AS | Assignment |
Owner name: MARSHALL, MR. BARRY J., AUSTRALIA Free format text: CORRECTED ASSIGNMENT FOR REEL/FRAME 015510/0200;ASSIGNOR:KIMBERLY-CLARK WORLDWIDE, INC.;REEL/FRAME:016095/0992 Effective date: 20040621 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20140307 |